Adial Pharmaceuticals Regains Nasdaq Compliance Following Reverse Stock Split
ADIL is trading near its 52-week low of $2.3 (11% above the low) on elevated volume (2.3× avg).
Summary
Adial Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving the delisting threat that prompted its recent reverse stock split.
Key Events · Corporate Governance and Compliance · ADIL
-
Regained Nasdaq Compliance
The company received a notice from Nasdaq confirming that its common stock maintained a closing bid price of $1.00 or greater for 10 consecutive business days (February 6-20, 2026), thereby regaining compliance with Listing Rule 5550(a)(2). Nasdaq has closed the matter.
-
Follows Reverse Stock Split
This compliance achievement directly follows the 1-for-25 reverse stock split that was announced on February 4, 2026, and implemented to meet Nasdaq's minimum bid price requirement.
-
Advanced Partnering Discussions
CEO Cary Claiborne highlighted that regaining compliance is an important milestone as the company advances AD04 toward its pivotal Phase 3 program and is engaged in advanced strategic partnering discussions to support its development and commercialization.
Analysis · ADIL · Life Sciences
Adial Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting threat. This positive development follows the 1-for-25 reverse stock split announced on February 4, 2026, which was specifically undertaken to address this issue. While the reverse split itself was a dilutive event, achieving compliance is crucial for the company's continued listing and access to capital markets. The CEO's comments about advanced strategic partnering discussions for AD04's Phase 3 program suggest a focus on future development and commercialization now that the compliance issue is resolved.
At the time of this filing, ADIL was trading at $2.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $2.30 to $32.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.